Literature DB >> 24421524

Alogliptin.

Dennis J Cada1, Terri L Levien2, Danial E Baker3.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The July 2013 monograph topics are prothrombin complex concentrate (human), cysteamine bitartrate delayed-release capsules, doxylamine succinate/pyridoxine hydrochloride, tedizolid phosphate, and sofosbuvir. The DUE/MUE is on canaglifozin.

Entities:  

Year:  2013        PMID： 24421524      PMCID： PMC3839527          DOI： 10.1310/hpj4807-580

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  22 in total

1.  Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.

Authors:  K Kaku; T Itayasu; S Hiroi; M Hirayama; Y Seino
Journal:  Diabetes Obes Metab       Date:  2011-11       Impact factor: 6.577

Review 2.  Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.

Authors:  Larry K Golightly; Caitlin C Drayna; Michael T McDermott
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

Review 3.  DPP-4 inhibitors: what may be the clinical differentiators?

Authors:  John Gerich
Journal:  Diabetes Res Clin Pract       Date:  2010-08-13       Impact factor: 5.602

4.  Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.

Authors:  B Eliasson; D Möller-Goede; K Eeg-Olofsson; C Wilson; J Cederholm; P Fleck; M Diamant; M-R Taskinen; U Smith
Journal:  Diabetologia       Date:  2012-01-12       Impact factor: 10.122

5.  Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.

Authors:  Paul Covington; Ronald Christopher; Michael Davenport; Penny Fleck; Qais A Mekki; Elisabeth R Wann; Aziz Karim
Journal:  Clin Ther       Date:  2008-03       Impact factor: 3.393

6.  Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.

Authors:  Yusuke Moritoh; Koji Takeuchi; Tomoko Asakawa; Osamu Kataoka; Hiroyuki Odaka
Journal:  Eur J Pharmacol       Date:  2008-04-10       Impact factor: 4.432

7.  The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice.

Authors:  Yusuke Moritoh; Koji Takeuchi; Tomoko Asakawa; Osamu Kataoka; Hiroyuki Odaka
Journal:  Eur J Pharmacol       Date:  2008-11-17       Impact factor: 4.432

8.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.

Authors:  R E Pratley; M S Kipnes; P R Fleck; C Wilson; Q Mekki
Journal:  Diabetes Obes Metab       Date:  2009-02       Impact factor: 6.577

Review 9.  Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2012-04-19       Impact factor: 19.112

10.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study.

Authors:  Ralph A DeFronzo; Penny R Fleck; Craig A Wilson; Qais Mekki
Journal:  Diabetes Care       Date:  2008-09-22       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.